Mankind Pharma Limited

₹2,540As of Sun 8 Nov 2026, 12:00 UTC
NSE:MANKINDHealthcare
Country India
PE (Fwd) •••
TSR 3Y CAGR 19.92%
Div yield 0.08%
ROE 13.56%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.43
PE TTM 46.83
TSR TTM 6.54%
Mkt cap ₹1.049T
ROIC 12.46%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹3,274
28.91%
(77.75%)
Sell 7|6|8|0|11
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
62.47
61.70
67.15
68.66
17.62%
14.72%
16.68%
16.10%
Revenue₹B
64.86
67.29
70.58
69.84
9.30%
15.91%
15.00%
13.27%
Peers (US$11.17B)
Cap (US$)
PE
12.14B
39.36x
11.03B
26.08x
Capital
TTM
5Y
10Y
Leveragex
6.385
(0.342)
(0.277)
EBIT/Intx
1.100
1.461
1.372
Own earn%
(42.67)
(116.25)
(113.17)
Sh yield%
24.36
34.22
31.21
Owners
Insiders/Inst%
14.59
42.40
Short interest%
5.21
SBC / revenue%
5.94
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
19–26
$1 testx
−0.1
Incr. ROIC%
11